Skip to Content

INCB-MA-MF-401:Heme: Myelofibrosis or Essential Thrombocythemia, Registry

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

Objective

Overview

The purpose of this prospective, longitudinal, noninterventional study is to describe clinical characteristics, evolution of disease burden, and treatment patterns in patients with select subcategories of essential thrombocythemia (ET) or myelofibrosis (MF).

Key Inclusion Criteria

For a patient to be eligible for participation in this study, all of the following criteria must apply.
  • MF cohort: Diagnosis of MF and low-risk using DIPSS risk categorization OR intermediate-1 risk by DIPSS by reason of age alone.
  • ET cohort: Diagnosis of ET and age ≥ 60 years OR history of thromboembolic events OR currently receiving ET-directed therapy (eg, hydroxyurea, anagrelide, interferon, busulfan, ruxolitinib, etc).
  • Willing and able to provide written informed consent.
  • Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel.
  • Under the supervision of a physician for the current care of MF or ET.

Key Exclusion Criteria

A patient will not be eligible for participation in this study if any of the following criteria apply.
  • Individuals who are participating in blinded investigational drug studies.
  • Individuals who are participating in Incyte investigational/interventional drug trials (company- or investigator-sponsored studies) until they have completed the 30-day end of study visit.
  • Life expectancy ≤ 6 months.
  • Diagnosis of secondary acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, or secondary thrombocytosis.

Phase: N/A

                          Learn More

                          IRB Protocol Number
                          INCB-MA-MF-401
                          Principal Investigator(s)
                          Asim Pati, M.D

                          Clinical Trial Categories

                          • Hematologic Cancer
                          Sponsor(s)
                          Incyte Corporation
                          How to Participate

                          Wanda Burdette, RN

                          864-560-6810

                          wburdette@gibbscc.org

                          Was this page helpful?

                          Yes
                          No

                          Thank you for your feedback!

                          Thank you for your feedback and helping us to improve our website.
                          There will be no additional response.

                          Upcoming Events

                          • Dec
                            17
                            Monday
                            5:45 PM - 6:45 PM
                            A guided tour of our labor, delivery and post-partum areas eases stress on the day of the delivery by allowing you to become familiar with the hospital, parking and waiting areas.
                          • Dec
                            18
                            Tuesday
                            9:00 AM - 9:30 AM
                            Prevent T2 is a year-long program which will help you learn lasting lifestyle changes that will help you reduce your chance of developing type 2 diabetes.

                          News & Highlights

                          Stay Connected!

                          Get the latest news on the health topics that matter most to you.

                          Sign up